ResearcherJiangnan UniversityActive in the last 2 years
Shuo Zhang
Matched on ORCID iD 0000-0002-1057-7255; OpenAlex author ID A5088104721. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 13
2021: 1 paper · 2022: none · 2023: 2 papers · 2024: none · 2025: 2 papers
Papers 5
- NAT10 regulates tumor progression and immune microenvironment in pancreatic ductal adenocarcinoma via the N4-acetylated LAMB3-mediated FAK/ERK pathway. Co-author DOI 10.1002/cac2.70045↗
- Targeting the ac4C 'Writer' NAT10 enhances pancreatic cancer immunotherapy via dual modulation of CD8+ T cells and tumor cells. Co-author DOI 10.1038/s41419-025-08156-0↗
- The DEAD-box RNA helicase, DDX60, Suppresses immunotherapy and promotes malignant progression of pancreatic cancer. Co-author DOI 10.1016/j.bbrep.2023.101488↗
- Linc00662 m6A promotes the progression and metastasis of pancreatic cancer by activating focal adhesion through the GTF2B-ITGA1-FAK pathway. Co-author PMID 37293163↗
- ACTR3 promotes cell migration and invasion by inducing epithelial mesenchymal transition in pancreatic ductal adenocarcinoma. First author DOI 10.21037/jgo-21-609↗
Closest collaborators
The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Leisheng Wang · 3 shared papers, 2023–2025 · strength 0.64
- Paper NAT10 regulates tumor progression and immune microenvironment in pancreatic ductal adenocarcinoma via the N4-acetylated… DOI 10.1002/cac2.70045↗
- Paper Targeting the ac4C 'Writer' NAT10 enhances pancreatic cancer immunotherapy via dual modulation of CD8+ T cells and tumo… DOI 10.1038/s41419-025-08156-0↗
- Paper The DEAD-box RNA helicase, DDX60, Suppresses immunotherapy and promotes malignant progression of pancreatic cancer. DOI 10.1016/j.bbrep.2023.101488↗
- Enhong Chen · 2 shared papers, 2025 · strength 0.45
- Paper NAT10 regulates tumor progression and immune microenvironment in pancreatic ductal adenocarcinoma via the N4-acetylated… DOI 10.1002/cac2.70045↗
- Paper Targeting the ac4C 'Writer' NAT10 enhances pancreatic cancer immunotherapy via dual modulation of CD8+ T cells and tumo… DOI 10.1038/s41419-025-08156-0↗
- Hao Hu · 2 shared papers, 2025 · strength 0.45
- Paper NAT10 regulates tumor progression and immune microenvironment in pancreatic ductal adenocarcinoma via the N4-acetylated… DOI 10.1002/cac2.70045↗
- Paper Targeting the ac4C 'Writer' NAT10 enhances pancreatic cancer immunotherapy via dual modulation of CD8+ T cells and tumo… DOI 10.1038/s41419-025-08156-0↗
- Tiantian Lai · 2 shared papers, 2023 · strength 0.36
- Xiaowen Su · 2 shared papers, 2023 · strength 0.36
- Hao Hu · 2 shared papers, 2021–2023 · strength 0.35
- Paper The DEAD-box RNA helicase, DDX60, Suppresses immunotherapy and promotes malignant progression of pancreatic cancer. DOI 10.1016/j.bbrep.2023.101488↗
- Paper ACTR3 promotes cell migration and invasion by inducing epithelial mesenchymal transition in pancreatic ductal adenocarc… DOI 10.21037/jgo-21-609↗
- Shudong Hu · 1 shared paper, 2025 · strength 0.22
- Hao Ye · 1 shared paper, 2025 · strength 0.22
- Changyong Zhao · 1 shared paper, 2023 · strength 0.17
- Minfeng Liu · 1 shared paper, 2023 · strength 0.17
- Hao Hu · 1 shared paper, 2023 · strength 0.17
- Junjing Zhou · 1 shared paper, 2023 · strength 0.17
- Yuanlong Gu · 1 shared paper, 2021 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.